Regulation of immune response to tumor antigen: interference with syngeneic tumor immunity by anti-IA alloantisera
- PMID: 106399
- PMCID: PMC383093
- DOI: 10.1073/pnas.76.2.920
Regulation of immune response to tumor antigen: interference with syngeneic tumor immunity by anti-IA alloantisera
Abstract
We present evidence for a role of I-A subregion-encoded determinants in syngeneic tumor immunity. In animals rendered immune to the S1509a fibrosarcoma, daily treatment with microliter quantities of antisera directed against Kk and I-Ak determinants expressed on lymphoid cells of host origin decreased the capacity for immune tumor rejection. Absorption studies revealed that anti-I-Ak antibody activity alone was sufficient for the manifestation of this effect. Furthermore, experiments utilizing F1 hybrids showed that an antiserum that was genetically unable to interact with H-2 determinants expressed on the tumor was equally effective in inhibiting tumor immunity. Suggestive evidence that the activity of this antiserum is related to interference with the generation of effector T cell function was provided by the observation that hyperimmune animals pretreated with an anti-Kk,I-Ak antiserum were no longer capable of adoptively transferring tumor immunity to naive recipients. Thus, it is possible to regulate the secondary immune response to tumor antigens by using antisera with specificity for I-A determinants expressed on cells or possibly on factors of the host lymphoid system.
Similar articles
-
In vivo effects of anti-Ia alloantisera. I. Elimination of specific suppression by in vivo administration of antisera specific for I-J controlled determinants.J Exp Med. 1978 Mar 1;147(3):656-66. doi: 10.1084/jem.147.3.656. J Exp Med. 1978. PMID: 75939 Free PMC article.
-
Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.J Immunol. 1993 Jul 1;151(1):244-55. J Immunol. 1993. PMID: 8326126
-
Regulation of the immune response to tumor antigens. III. Characterization of thymic suppressor factor(s) produced by tumor-bearing hosts.J Immunol. 1977 Aug;119(2):757-64. J Immunol. 1977. PMID: 69667
-
Differential antigen presentation in tumor immunity.Fed Proc. 1984 Jun;43(9):2460-4. Fed Proc. 1984. PMID: 6327399 Review.
-
The present status of tumor immunology.Adv Surg. 1971;5:189-254. Adv Surg. 1971. PMID: 4941820 Review. No abstract available.
Cited by
-
Suppressor mechanisms in tumor immunity.Experientia. 1983 Mar 15;39(3):235-42. doi: 10.1007/BF01955286. Experientia. 1983. PMID: 6186519 Review.
-
In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis.Proc Natl Acad Sci U S A. 1981 Nov;78(11):7111-4. doi: 10.1073/pnas.78.11.7111. Proc Natl Acad Sci U S A. 1981. PMID: 6947275 Free PMC article.
-
Early development of the T cell repertoire. In vivo treatment of neonatal mice with anti-Ia antibodies interferes with differentiation of I-restricted T cells but not K/D-restricted T cells.J Exp Med. 1983 Jun 1;157(6):1932-46. doi: 10.1084/jem.157.6.1932. J Exp Med. 1983. PMID: 6222135 Free PMC article.
-
Mechanism of regulation of immune responses by in vivo administration of monoclonal anti-I-A antibodies.Surv Immunol Res. 1985;4(3):173-8. doi: 10.1007/BF02918670. Surv Immunol Res. 1985. PMID: 2935910 No abstract available.
-
Functional association of idiotypic and I-J determinants on the antigen receptor of suppressor T cells.Proc Natl Acad Sci U S A. 1981 Jul;78(7):4557-61. doi: 10.1073/pnas.78.7.4557. Proc Natl Acad Sci U S A. 1981. PMID: 6170068 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources